- Home
- LEA vs GH Comparison
LEA vs GH Comparison
Compare LEA & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEA
- GH
- Stock Information
- Founded
- LEA 1917
- GH 2011
- Country
- LEA United States
- GH United States
- Employees
- LEA N/A
- GH N/A
- Industry
- LEA Auto Parts:O.E.M.
- GH Medical Specialities
- Sector
- LEA Consumer Discretionary
- GH Health Care
- Exchange
- LEA Nasdaq
- GH Nasdaq
- Market Cap
- LEA 5.4B
- GH 4.9B
- IPO Year
- LEA N/A
- GH 2018
- Fundamental
- Price
- LEA $103.52
- GH $92.41
- Analyst Decision
- LEA Buy
- GH Strong Buy
- Analyst Count
- LEA 11
- GH 22
- Target Price
- LEA $115.91
- GH $66.27
- AVG Volume (30 Days)
- LEA 499.9K
- GH 2.1M
- Earning Date
- LEA 10-31-2025
- GH 10-29-2025
- Dividend Yield
- LEA 2.96%
- GH N/A
- EPS Growth
- LEA N/A
- GH N/A
- EPS
- LEA 8.57
- GH N/A
- Revenue
- LEA $22,889,700,000.00
- GH $902,569,000.00
- Revenue This Year
- LEA N/A
- GH $28.28
- Revenue Next Year
- LEA $1.85
- GH $23.00
- P/E Ratio
- LEA $12.15
- GH N/A
- Revenue Growth
- LEA N/A
- GH 30.38
- 52 Week Low
- LEA $73.85
- GH $21.28
- 52 Week High
- LEA $113.10
- GH $73.31
- Technical
- Relative Strength Index (RSI)
- LEA 57.89
- GH 79.81
- Support Level
- LEA $100.70
- GH $68.02
- Resistance Level
- LEA $103.58
- GH $73.31
- Average True Range (ATR)
- LEA 2.25
- GH 3.29
- MACD
- LEA 0.63
- GH 1.43
- Stochastic Oscillator
- LEA 92.20
- GH 87.72
About LEA Lear Corporation
Lear Corp designs, develops, and manufactures automotive seating and electrical systems and components. The company has two reporting segments Seating and E-Systems. Seating components include frames and mechanisms, covers (leather and woven fabric), seat heating and cooling, foam, and headrests. Automotive electrical distribution and connection systems and electronic systems include wiring harnesses, terminals and connectors, on-board battery chargers, high-voltage battery management systems. The company earns majority of its revenue from the seating segment.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.